Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20230029594BODY FAT REDUCING AGENT AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF REDUCING BODY FAT
US 02.02.2023
Int.Class C12Q 1/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
Appl.No 17788524 Applicant OSAKA UNIVERSITY Inventor Shizuo AKIRA

The present invention provides a body fat reducing agent comprising a Regnase-1 inhibitor as an active ingredient, and a method for screening for a substance capable of reducing body fat, the method comprising selecting a substance capable of inhibiting the expression of Regnase-1 or a substance capable of inhibiting the function of Regnase-1. The body fat reducing agent of the present invention is useful for improving metabolic syndrome, and for preventing and/or treating fatty liver disease, including nonalcoholic steatohepatitis (NASH). The screening method of the present invention can be used to identify a useful substance capable of reducing body fat.

2.20230030983FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US 02.02.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 17655519 Applicant ASTEX THERAPEUTICS LTD Inventor Jayaprakash KARKERA

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

3.20230033537METHOD OF PRODUCING ADM COLLAGEN FIBER, ADM COLLAGEN FIBER PRODUCED USING METHOD, AND APPARATUS FOR PRODUCING ADM COLLAGEN FIBER
US 02.02.2023
Int.Class C07K 14/78
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
Appl.No 17792608 Applicant GENEWEL CO., LTD. Inventor Hong Doo KIM

The present invention relates to a method of producing an ADM collagen fiber, an ADM collagen fiber produced using the method, and an apparatus for producing the ADM collagen fiber. More particularly, the present invention relates to a method of producing an ADM collagen fiber including a step of extruding an acidic ADM collagen solution into a basic solution to form filaments. The present invention has an effect of providing a method of producing an ADM collagen fiber, an ADM collagen fiber produced using the method, and an apparatus for producing the ADM collagen fiber. According to the present invention, since a collagen solution raw material having a required concentration may be prepared by immediately pulverizing ADM collagen shells, economic efficiency and productivity may be increased through reduction in production cost and time. In addition, mass production is possible by using a continuous process apparatus with a simple structure.

4.WO/2023/006919HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
WO 02.02.2023
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
Appl.No PCT/EP2022/071275 Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Inventor HENNINO, Ana
The tumoral stroma evolution during cancer is playing a key role as it may acts as a physical barrier limiting access of the immune cells to the tumor. Thus, βig-h3 (TGFβi) overexpression in the stroma is of bad prognosis in Pancreatic Ductal Adenocarcinoma and in other cancers. A monoclonal antibody against βig-h3 protein called 18B3 was shown playing a role in directly modulating the anti-tumoral immune response by blocking inhibiting CD8+ T cell activation. From 18B3 the inventors developed humanized antibodies having unexpectedly high affinity, slow dissociation rate and strong thermal stability making them powerful candidates for treating cancers wherein the stroma expresses βig-h3 in vivo. The invention thus relates to these humanized monoclonal antibodies and methods of treatment of such cancers.
5.WO/2023/009754PROTEIN-ANTIVIRAL COMPOUND CONJUGATES
WO 02.02.2023
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No PCT/US2022/038723 Applicant REGENERON PHARMACEUTICALS, INC. Inventor NITTOLI, Thomas
Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.
6.WO/2023/008404REAGENT CONTAINING HUMANIZED ANTIBODY
WO 02.02.2023
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/JP2022/028698 Applicant DENKA COMPANY LIMITED Inventor ISHIKAWA Haruto
Provided are a reagent using an antibody that is capable of reducing a nonspecific reaction, a kit for measuring an antigen, and a method for measuring an antigen. An immunological assay reagent that contains a humanized antibody against a substance to be assayed.
7.WO/2023/009979METHODS OF TREATING ULCERATIVE COLITIS WITH ANTI-LIGHT ANTIBODIES
WO 02.02.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/074106 Applicant AVALO THERAPEUTICS, INC. Inventor NEIL, Garry, A.
The present disclosure relates to methods of treating ulcerative colitis with anti-LIGHT antibodies. The disclosure also relates to assaying free LIGHT prior to, during, or after administration of an anti-LIGHT antibody to treat ulcerative colitis.
8.WO/2023/010054ANTI-CCR8 ANTIBODIES
WO 02.02.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/US2022/074214 Applicant ABBVIE INC. Inventor MCCLUSKEY, Andrew, J.
The present disclosure provides anti-CCR8 antibodies, including compositions and methods of using such antibodies.
9.WO/2023/008974DUAL FUNCTIONAL COSMETIC COMPOSITIONS AND PREPARATION METHOD THEREFOR
WO 02.02.2023
Int.Class C07K 14/50
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
50Fibroblast growth factor (FGF)
Appl.No PCT/KR2022/011256 Applicant UBIPROTEIN CORP Inventor KIM, Myung-Sun
The present invention relates to a method for extending a half-life of a protein, the method comprising substituting one lysine residue in each of the amino acid sequences in two proteins, or to a protein having an extended half-life. The protein in which lysine residues have been substituted according to the present invention persists in the body for an extended period of time, and exhibits excellent treatment results. In addition, two kinds of proteins can be produced and provided in a single production process.
10.WO/2023/009770METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY
WO 02.02.2023
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/038749 Applicant TEVOGEN BIO, INC. Inventor SAADI, Ryan
Disclosed herein are methods of preparing peptide specific cytotoxic T cells (CTLs) against an emerged strain of a virus. The methods include providing an initial peptide composition specific to a prior strain of a virus, against which prior CTLs were sensitized, wherein the prior CTLs have reduced efficacy against an emerged strain of a virus relative to their efficacy against the prior strain of the virus; identifying an immunodominant peptide against a prior strain of a virus in an initial peptide composition; reducing the proportion of an immunodominant peptide in an initial peptide composition to yield an immunodominant-peptide- diluted peptide composition; and sensitizing mononuclear cells with an immunodominant- peptide-diluted peptide composition, thereby producing expansion of the peptide specific CTLs against an emerged strain of a virus. The virus can be SARS-COV2 (COVID-19) and the emerged strain can be Delta or Omicron BA.2.75.